The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2019 | Key population-based registry studies in hematological oncology
Magnus Björkholm, MD, PhD, of the Karolinska Institute, Stockholm, Sweden, speaks at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany. He discusses key examples of where population-based registry studies have answered questions in the field of hematological oncology, including chronic lymphocytic leukemia, multiple myeloma and myeloproliferative neoplasms.
